Art
J-GLOBAL ID:200902201923970131   Reference number:08A0328874

呼吸器疾患における医師主導臨床試験の取り組みと将来展望 肺癌:遺伝子発現パターンによるゲフィチニブ感受性予測

Author (3):
Material:
Volume: 12  Issue:Page: 149-154  Publication year: Apr. 01, 2008 
JST Material Number: L3361A  ISSN: 1342-436X  CODEN: BUKOFC  Document type: Article
Article type: 文献レビュー  Country of issue: Japan (JPN)  Language: JAPANESE (JA)
Thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
Semi thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.

   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=08A0328874&from=J-GLOBAL&jstjournalNo=L3361A") }}
JST classification (3):
JST classification
Category name(code) classified by JST.
Drug therapy(=pharmacotherapy)for tumors  ,  Tumors(=neoplasms)of respiratory system  ,  Clinical application of antitumor(=antineoplastic)drugs 
Substance index (1):
Substance index
Chemical Substance indexed to the Article.
Reference (10):
  • Paik S et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
  • Lynch TJ et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004
  • Cobo M et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-smallcell lung cancer. J Clin Oncol 25: 2747-2754, 2007
  • Thatcher N et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005
  • Fukuoka M et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 2237-2246, 2003
more...

Return to Previous Page